PDS Biotechnology (PDSB) Interest & Investment Income (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Interest & Investment Income came in at $224659.0 in Q4 2025, down 55.42% YoY from $503942.0 in Q4 2024, and down 20.08% on a QoQ basis from $281109.0 in Q3 2025.
PDS Biotechnology (PDSB) Interest & Investment Income (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Interest & Investment Income data on file, last reported at $224659.0 in Q4 2025.
- Quarterly Interest & Investment Income fell 55.42% year-over-year to $224659.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 51.6% YoY) and the FY2025 annual result came in at $1.2 million, down 51.6% from the prior year.
- Interest & Investment Income declined to $224659.0 in Q4 2025, from $281109.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $750654.0 in Q2 2023 to a low of $604.0 in Q2 2021.
- A 5-year average of $378726.2 and a median of $355736.5 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income slumped 98.59% — and 2022, when it surged 34767.67%.
- Tracing PDSB's Interest & Investment Income over 5 years: stood at $1729.0 in 2021, then surged by 34767.67% to $602862.0 in 2022, then advanced by 13.38% to $683540.0 in 2023, then fell by 26.27% to $503942.0 in 2024, then sank by 55.42% to $224659.0 in 2025.
- The last three Interest & Investment Income figures came in at $224659.0 (Q4 2025), $281109.0 (Q3 2025), and $333624.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | -3.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125,405.00 |
| Dec 31, 2025 | 224,659.00 |
| Sep 30, 2025 | 281,109.00 |
| Jun 30, 2025 | 333,624.00 |
| Mar 31, 2025 | 377,849.00 |
| Dec 31, 2024 | 503,942.00 |
| Sep 30, 2024 | 666,770.00 |
| Jun 30, 2024 | 675,209.00 |
| Mar 31, 2024 | 668,895.00 |
| Dec 31, 2023 | 683,540.00 |
| Sep 30, 2023 | 739,404.00 |
| Jun 30, 2023 | 750,654.00 |
| Mar 31, 2023 | 729,341.00 |
| Dec 31, 2022 | 602,862.00 |
| Sep 30, 2022 | 252,073.00 |
| Jun 30, 2022 | 74,547.00 |
| Mar 31, 2022 | 5,700.00 |
| Dec 31, 2021 | 1,729.00 |
| Sep 30, 2021 | 1,358.00 |
| Jun 30, 2021 | 604.00 |